 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- 'CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences,
  Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies
  for genetically defined diseases, today announced Andrew Robbins, Chief Executive
  Officer and President, will participate ...'


Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference

---
- Cogent Biosciences, Inc. (NASDAQ:UMRX) shares reached a new 52-week high on Monday
  . The company traded as high as $12.24 and last traded at $12.10, with a volume
  of 201381 shares trading hands. The stock had previously closed at $11.91. UMRX
  has been the topic of a number of research analyst ...


Cogent Biosciences (NASDAQ:UMRX) Hits New 52-Week High at $12.24

---
- Cogent Biosciences (NASDAQ:UMRX) will be releasing its earnings data before the
  market opens on Thursday, November 12th. Analysts expect Cogent Biosciences to post
  earnings of ($0.56) per share for the quarter. Cogent Biosciences (NASDAQ:UMRX)
  last posted its quarterly earnings data on Tuesday, ...


Cogent Biosciences (UMRX) Scheduled to Post Earnings on Thursday

---
- Cogent Biosciences (NASDAQ:UMRX) and Rezolute (OTCMKTS:RZLTD) are both small-cap
  medical companies, but which is the better business? We will compare the two companies
  based on the strength of their risk, institutional ownership, valuation, dividends,
  analyst recommendations, profitability and ...


Cogent Biosciences (NASDAQ:UMRX) vs. Rezolute (NASDAQ:RZLTD) Head-To-Head Survey

---
- Vectura Group (OTCMKTS:VEGPF) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap
  medical companies, but which is the superior stock? We will contrast the two companies
  based on the strength of their valuation, profitability, risk, earnings, institutional
  ownership, analyst recommendations and ...


Head-To-Head Contrast: Vectura Group (OTCMKTS:VEGPF) and Cogent Biosciences (OTCMKTS:UMRX)

---
- The fool doth think he is wise, but the wise man knows himself to be a fool." -
  William Shakespeare, As You Like It Today, we take our first look at a very volatile
  Busted IPO. Recent events and some beneficial owner purchases put this small cap
  on our radar for further research.


Unraveling The Investment Case For Unum Therapeutics

---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 100,000
  shares of the companys stock in a transaction dated Friday, May 8th. The stock was
  sold at an average price of $0.46, for a total transaction of $46,000.00. The sale
  was disclosed in a legal filing with the ...


Dario Campana Sells 100,000 Shares of Unum Therapeutics Inc (NASDAQ:UMRX) Stock

---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 100,000
  shares of the businesss stock in a transaction dated Monday, May 11th. The shares
  were sold at an average price of $0.45, for a total value of $45,000.00. The sale
  was disclosed in a filing with the Securities &#...


---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 98,973
  shares of the companys stock in a transaction on Tuesday, April 14th. The stock
  was sold at an average price of $0.40, for a total value of $39,589.20. The transaction
  was disclosed in a filing with the SEC, which...


Dario Campana Sells 98,973 Shares of Unum Therapeutics Inc (NASDAQ:UMRX) Stock

---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 242,579
  shares of Unum Therapeutics stock in a transaction on Monday, April 27th. The stock
  was sold at an average price of $0.40, for a total value of $97,031.60. The transaction
  was disclosed in a legal filing with the SEC, ...


Dario Campana Sells 242,579 Shares of Unum Therapeutics Inc (NASDAQ:UMRX) Stock

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Watchers	1,886
52-Wk Low	$0.295
52-Wk High	$3.72

Market Cap	$105.32M
Volume (M)	6,068.00
52-Wk High	$3.72
52-Wk Low	$0.295

Current Price	$2.50
Prev Close	$2.53
Open	$2.56
Dividend Yield	0.00%
50-Day Moving Average	$2.61
Beta	0.84
Avg. Volume	502,242.95
PE Ratio	N/A

52-Week High	$3.72
52-Week Low	$0.295
Market Capitalization	$105.32M
EPS	-$0.7551
Price to Book	4.02
Revenue Per Employee	$331,486.11
Enterprise Value/EBITDA	0.08

UMRX Unum Therapeutics Inc.

About

Feed

News

Fundamentals